Close

PerkinElmer Elects Peter Barrett to Board of Directors

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

UCB Reports New EADV Data on Bimekizumab Treatment in HS

UCB has announced new three-year data for bimekizumab in...

CPHI Sustainability Summit Targets Practical Pharma Action

CPHI Milan will host the inaugural CPHI Sustainability Summit...

Sterling Expands ADC Manufacturing Capacity and Capabilities

Contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions...
- Advertisement -

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that Peter Barrett, a partner at Atlas Venture, an early stage technologies and life sciences venture capital fund, has been elected to the Company’s Board of Directors, in anticipation of a current Board member reaching retirement age.

โ€œWe are very excited to have Peter joining our Board,โ€ said Robert F. Friel, chairman and chief executive officer of PerkinElmer, Inc. โ€œPeter brings decades of deep industry experience and knowledge of life sciences and analytical instrumentation, gained in his international leadership positions, as well as from his expertise as a leading investor in scientific enterprises.โ€

Prior to joining Atlas Venture in 2002 where he is focused on developing new life science technologies, Barrett was a co-founder, executive vice president and chief business officer of Celera Genomics. Previously, Barrett held senior management positions at the former Perkin-Elmer Corporation throughout the 1980s and 1990s, where he expanded the Companyโ€™s business presence in key segments and geographies.

Peter received his Bachelor of Science in Chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his PhD in Analytical Chemistry from Northeastern University.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com.

ย 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Latest stories

Related stories

UCB Reports New EADV Data on Bimekizumab Treatment in HS

UCB has announced new three-year data for bimekizumab in...

CPHI Sustainability Summit Targets Practical Pharma Action

CPHI Milan will host the inaugural CPHI Sustainability Summit...

Sterling Expands ADC Manufacturing Capacity and Capabilities

Contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions...

eschbach Launches New Digital Leader Standard Work Capability for Pharma Process Operations

Seqonis Intelligent Operations by eschbach has a new dedicated...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป